{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T03:32:59Z","timestamp":1787110379608,"version":"build-2736575974"},"reference-count":10,"publisher":"The Pediatric Pharmacy Association","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022]]},"abstract":"Teriparatide is a human parathyroid hormone analog approved for the treatment of osteoporosis in adult patients. Its use for hypocalcemia and hypoparathyroidism in the pediatric population is described through case reports and small case series; however, larger studies that demonstrate long-term efficacy and safety are limited. At our institution, a 4-month-old premature (gestational age: 32 weeks) infant with multiple congenital anomalies, functional athymia, and severe hypoparathyroidism and receiving calcitriol, vitamin D, and calcium carbonate supplementation was initiated on subcutaneous injection of teriparatide. During the course of treatment, her calcium carbonate, vitamin D, and calcitriol supplementation requirements substantially decreased. Teriparatide effectively increased serum ionized calcium concentrations and decreased serum phosphorus concentrations in the present case-study over a 6-month period. Teriparatide was well tolerated, and no evidence of hypercalcemia was observed throughout treatment.<\/jats:p>","DOI":"10.5863\/1551-6776-27.1.80","type":"journal-article","created":{"date-parts":[[2021,12,22]],"date-time":"2021-12-22T19:58:51Z","timestamp":1640203131000},"page":"80-84","source":"Crossref","is-referenced-by-count":3,"title":["Teriparatide Therapy in a 4-Month-Old With Severe Hypoparathyroidism"],"prefix":"10.5863","volume":"27","author":[{"given":"Neelam D.","family":"Bhatt","sequence":"first","affiliation":[{"name":"Department of Pharmacy Services (NDB, JLH), Shawn Jenkins Children's Hospital, Charleston, SC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie L.","family":"Heh","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Services (NDB, JLH), Shawn Jenkins Children's Hospital, Charleston, SC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle P.","family":"Hudspeth","sequence":"additional","affiliation":[{"name":"Division of Pediatric Hematology\/Oncology (MPH), Shawn Jenkins Children's Hospital, Charleston, SC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelli W.","family":"Williams","sequence":"additional","affiliation":[{"name":"Division of Pediatric Pulmonology, Allergy & Immunology (KWW), Shawn Jenkins Children's Hospital, Charleston, SC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine E.","family":"Twombley","sequence":"additional","affiliation":[{"name":"Division of Pediatric Nephrology (KET), Shawn Jenkins Children's Hospital, Charleston, SC"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3883","reference":[{"issue":"1","key":"i1551-6776-27-1-80-b1","series-title":"Acta Biomed","first-page":"122","article-title":"Current treatment of hypoparathyroidism: theory versus reality waiting guidelines for children and adolescents","volume":"89","year":"2018","unstructured":"Di Maio\n S,\n \n \n Soliman\n AT,\n \n \n De Sanctis\n V,\n \n \n .\n\t\t\t\t\tCurrent treatment of hypoparathyroidism: theory versus reality waiting guidelines for children and adolescents.\n\t\t\t\t\tActa Biomed.\n\t\t\t\t\t2018;\n\t\t\t\t\t89(\n\t\t\t\t\t1):\n\t\t\t\t\t122\u2013\n\t\t\t\t\t131."},{"key":"i1551-6776-27-1-80-b2","article-title":"Teriparatide [package insert]","year":"2002","unstructured":"Teriparatide [package insert].\n\t\t\t\t\tIndianapolis, IN:\n\t\t\t\t\tEli Lilly and Company;\n\t\t\t\t\t2002."},{"issue":"12","key":"i1551-6776-27-1-80-b3","series-title":"J Bone Miner Res","first-page":"2033","article-title":"Lack of bone neoplasms and persistence of bone efficacy in cynomolgus macaques after long-term treatment with teriparatide [rhPTH(1\u201334)]","volume":"23","year":"2008","unstructured":"Vahle\n JL,\n \n \n Zuehlke\n U,\n \n \n Schmidt\n A,\n \n \n .\n\t\t\t\t\tLack of bone neoplasms and persistence of bone efficacy in cynomolgus macaques after long-term treatment with teriparatide [rhPTH(1\u201334)].\n\t\t\t\t\tJ Bone Miner Res.\n\t\t\t\t\t2008;\n\t\t\t\t\t23(\n\t\t\t\t\t12):\n\t\t\t\t\t2033\u2013\n\t\t\t\t\t2039."},{"issue":"12","key":"i1551-6776-27-1-80-b4","series-title":"J Bone Miner Res","first-page":"2429","article-title":"The US post-marketing surveillance study of adult osteosarcoma and teriparatide: study design and findings from the first 7 years","volume":"27","year":"2012","unstructured":"Andrews\n EB,\n \n \n Gilsenan\n AW,\n \n \n Midkiff\n K,\n \n \n .\n\t\t\t\t\tThe US post-marketing surveillance study of adult osteosarcoma and teriparatide: study design and findings from the first 7 years.\n\t\t\t\t\tJ Bone Miner Res.\n\t\t\t\t\t2012;\n\t\t\t\t\t27(\n\t\t\t\t\t12):\n\t\t\t\t\t2429\u2013\n\t\t\t\t\t2437."},{"issue":"9","key":"i1551-6776-27-1-80-b5","series-title":"Arch Dis Child","first-page":"e2","article-title":"Use of teriparatide in a four year old patient with autosomal dominant hypocalcaemia","volume":"101","year":"2016","unstructured":"Fox\n A,\n \n \n Gilbert\n R.\n \n \n Use of teriparatide in a four year old patient with autosomal dominant hypocalcaemia.\n\t\t\t\t\tArch Dis Child.\n\t\t\t\t\t2016;\n\t\t\t\t\t101(\n\t\t\t\t\t9):\n\t\t\t\t\te2."},{"issue":"4","key":"i1551-6776-27-1-80-b6","series-title":"Horm Res Paediatr","first-page":"271","article-title":"Continuous subcutaneous recombinant parathyroid hormone (1\u201334) infusion in the management of childhood hypoparathyroidism associated with malabsorption","volume":"89","year":"2018","unstructured":"Linglart\n A,\n \n \n Saraff\n V,\n \n \n Rothenbuhler\n A,\n \n \n .\n\t\t\t\t\tContinuous subcutaneous recombinant parathyroid hormone (1\u201334) infusion in the management of childhood hypoparathyroidism associated with malabsorption.\n\t\t\t\t\tHorm Res Paediatr.\n\t\t\t\t\t2018;\n\t\t\t\t\t89(\n\t\t\t\t\t4):\n\t\t\t\t\t271\u2013\n\t\t\t\t\t277."},{"issue":"6","key":"i1551-6776-27-1-80-b7","series-title":"J Clin Endocrinol Metab","first-page":"2680","article-title":"Long-term treatment of 12 children with chronic hypoparathyroidism: a randomized trial comparing synthetic human parathyroid hormone 1\u201334 versus calcitriol and calcium","volume":"95","year":"2010","unstructured":"Winer\n K,\n \n \n Sinaii\n N,\n \n \n Reynolds\n J,\n \n \n .\n\t\t\t\t\tLong-term treatment of 12 children with chronic hypoparathyroidism: a randomized trial comparing synthetic human parathyroid hormone 1\u201334 versus calcitriol and calcium.\n\t\t\t\t\tJ Clin Endocrinol Metab.\n\t\t\t\t\t2010;\n\t\t\t\t\t95(\n\t\t\t\t\t6):\n\t\t\t\t\t2680\u2013\n\t\t\t\t\t2688."},{"key":"i1551-6776-27-1-80-b8","series-title":"J Pediatr","first-page":"391","article-title":"Long-term parathyroid hormone 1\u201334 replacement therapy in children with hypoparathyroidism","volume":"203","year":"2018","unstructured":"Winer\n K,\n \n \n Kelly\n A,\n \n \n Johns\n A,\n \n \n .\n\t\t\t\t\tLong-term parathyroid hormone 1\u201334 replacement therapy in children with hypoparathyroidism.\n\t\t\t\t\tJ Pediatr.\n\t\t\t\t\t2018;\n\t\t\t\t\t203:\n\t\t\t\t\t391\u2013\n\t\t\t\t\t399.e1."},{"issue":"2","key":"i1551-6776-27-1-80-b9","series-title":"Endocrine","first-page":"457","article-title":"Teriparatide (rhPTH 1\u201334) treatment in the pediatric age: long-term efficacy and safety data in a cohort with genetic hypoparathyroidism","volume":"67","year":"2020","unstructured":"Tuli\n G,\n \n \n Buganza\n R,\n \n \n Tessaris\n D,\n \n \n .\n\t\t\t\t\tTeriparatide (rhPTH 1\u201334) treatment in the pediatric age: long-term efficacy and safety data in a cohort with genetic hypoparathyroidism.\n\t\t\t\t\tEndocrine.\n\t\t\t\t\t2020;\n\t\t\t\t\t67(\n\t\t\t\t\t2):\n\t\t\t\t\t457\u2013\n\t\t\t\t\t465."},{"issue":"2","key":"i1551-6776-27-1-80-b10","series-title":"J Pediatr","first-page":"345","article-title":"Recombinant parathyroid hormone therapy for severe neonatal hypoparathyroidism","volume":"160","year":"2011","unstructured":"Cho\n Y,\n \n \n Tchan\n M,\n \n \n Roy\n B,\n \n \n .\n\t\t\t\t\tRecombinant parathyroid hormone therapy for severe neonatal hypoparathyroidism.\n\t\t\t\t\tJ Pediatr.\n\t\t\t\t\t2011;\n\t\t\t\t\t160(\n\t\t\t\t\t2):\n\t\t\t\t\t345\u2013\n\t\t\t\t\t348."}],"container-title":["The Journal of Pediatric Pharmacology and Therapeutics"],"original-title":[],"link":[{"URL":"https:\/\/jppt.kglmeridian.com\/view\/journals\/jppt\/27\/1\/article-p80.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/meridian.allenpress.com\/jppt\/article-pdf\/27\/1\/80\/2989933\/i1551-6776-27-1-80.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jppt.kglmeridian.com\/downloadpdf\/journals\/jppt\/27\/1\/article-p80.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jppt.kglmeridian.com\/downloadpdf\/journals\/jppt\/27\/1\/article-p80.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:35:16Z","timestamp":1747355716000},"score":1,"resource":{"primary":{"URL":"https:\/\/jppt.kglmeridian.com\/view\/journals\/jppt\/27\/1\/article-p80.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":10,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.5863\/1551-6776-27.1.80","relation":{},"ISSN":["1551-6776"],"issn-type":[{"value":"1551-6776","type":"print"}],"subject":[],"published":{"date-parts":[[2022]]}}}